Sintilimab FDA Approval Status
FDA Approved: No
Generic name: sintilimab
Company: Eli Lilly and Company
Treatment for: Non Small Cell Lung Cancer
Sintilimab is an investigational PD-1 inhibitor in development for the treatment of patients with nonsquamous non-small cell lung cancer (NSCLC).
Development timeline for sintilimab
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.